Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Informed source to Al Mayadeen: SDF Commander-in-Chief Mazloum Abdi demands that al-Sharaa approve the establishment of an autonomous region similar to the Kurdistan Region of Iraq.
Israeli media: Three drones launched from Yemen toward Eilat in span of 20 minutes.
Qatari Foreign Ministry: "Israel" should have already ceased fire under Trump plan for Gaza
Qatari Foreign Ministry: Release of Israeli captives will mark end of war in Gaza in accordance with Trump plan.
Israeli media: Security incident in Gaza Strip classified as serious results in six wounded soldiers so far, two critically injured.
Al Mayadeen's correspondent in South Lebanon: Israeli drone strike targets vehicle in Deir Ames, Tyre governorate.
Lebanese Ministry of Health: Final toll from airstrike on car in Zebdine, Nabatieh District: Two martyrs, four injured
Egyptian media: Indirect talks between Hamas and Israelis begin in Sharm el-Sheikh.
AFP: France's new PM Sebastein Lecornu resigns just hours after unveiling cabinet.
Trump: Technical teams will meet again on Monday in Egypt to discuss and clarify the final details, and the first phase is scheduled to be completed this week

New cancer treatment offers hope to patients out of options

  • By Al Mayadeen English
  • Source: Agencies
  • 22 Aug 2022 08:45
4 Min Read

Oncologists in the UK discover that combining immunotherapy with guadecitabine, a novel investigational medicine, can reverse cancer's resistance to immunotherapy.

  • x
  • New cancer treatment offers hope to patients out of options.
    New cancer treatment offers hope to patients out of options.

A newly discovered cancer treatment can stop the disease from advancing in patients who are resistant to immunotherapy. 

Immunotherapy is a type of cancer treatment that employs the immune system to target and kill cancer cells. It can save lives when other treatment choices, such as surgery, radiotherapy, or chemotherapy, have failed. Treatment cannot, however, benefit all patients, and some tumors can adapt to resist it.

Oncologists in the United Kingdom have discovered that combining immunotherapy with guadecitabine, a novel investigational medicine, can reverse cancer's resistance to immunotherapy. They discovered that patients who were anticipated to die after exhausted all therapy options lived far longer.

Read next: Almost half of cancer deaths connected to preventable factors: Study

The combination of immunotherapy medicine pembrolizumab and next-generation DNA hypomethylating agent guadecitabine slowed the progression of cancer in more than a third of patients enrolled in the early phase 1 trial. The findings were published in the Journal for ImmunoTherapy of Cancer.

The combination could become an effective weapon against different forms of cancer, experts revealed at the Institute of Cancer Research and Royal Marsden NHS foundation trust. 

Patients in the trial, from the Royal Marsden and University College London hospital, included those with lung, breast, prostate, and bowel cancer.

Treatment 

Related News

Russia to begin treating patients with AI-designed cancer vaccine

Russia completes preclinical trials of cancer vaccine, seeks approval

The study used pembrolizumab and guadecitabine to treat 34 cancer patients, 30 of whom had their tumors analyzed for immune activity and cancer growth. Every three weeks for three years, they had an injection of guadecitabine for four days in a row – and pembrolizumab on the first of those days.

Pembrolizumab is an immune checkpoint inhibitor drug that has already proved successful in treating a range of cancers, including lung and skin cancers. However, tumors can develop resistance to it and some patients who initially benefit will eventually get sicker.

Read next: AI tool accurately predicts tumor regrowth in cancer patients

The study lead, Anna Minchom, a clinical scientist at the Institute of Cancer Research and a consultant medical oncologist at the Royal Marsden, said: “Immunotherapy has shown amazing promise in cancer care over the last decade, but it doesn’t work well in all cancers and cancers can often become resistant. This combination might be a way to target their cancer even after it has stopped responding to immunotherapy.”

Guadecitabine may help overcome this resistance, doctors, researchers and scientists involved in the trial have discovered.

37% record no tumor progression 

The tumor stopped progressing in 37% of the 30 patients whose cancer activity was studied, during 24 weeks or more. Prior to the experiment, three-fifths of the cohort (60%) were resistant to immunotherapy. Almost four in ten (39%) did not become ill as a result of the drug combination.

The new treatment could help lung cancer patients. Of those resistant to immunotherapy, half had their disease controlled for 24 weeks or more.

A patient from Dorset, Alison Sowden, was diagnosed with lung cancer four years ago and was told she had a year to live, but then received pembrolizumab for three years. She is now free of cancer.

“I know there is a chance that my cancer may come back and develop resistance to treatment, so it is reassuring to know research efforts aiming to reverse cancer’s resistance to immunotherapy are under way,” she said.

“I hope this new experimental drug combination will eventually make it to the clinic and help people who have developed resistance to pembrolizumab.”

  • Cancer
  • United Kingdom

Most Read

Iraq at a crossroads: A new war front?

Iraq at a crossroads: A new war front?

  • West Asia
  • 30 Sep 2025
Tucker Carlson speaks at a memorial for Charlie Kirk, Sunday, September 21, 2025, at State Farm Stadium in Glendale, Arizona (AP)

Tucker Carlson: Israeli officers gave orders on Iran inside Pentagon

  • Politics
  • 2 Oct 2025
A Hamas fighter in combat fatigues stands before the ceremony for the handover of Israeli captives to the Red Cross in Nuseirat, central Gaza Strip, Saturday, February 22, 2025 (AP)

Hamas responds to Trump plan, backs Gaza withdrawal, exchange

  • Politics
  • 3 Oct 2025
ap

'Israel' pays influencers $7K per post to whitewash Gaza genocide

  • Politics
  • 1 Oct 2025

Coverage

All
War on Gaza

Read Next

All
Hezbollah's representative in Iran, Sayyed Abdullah Safieddine, during an interview with Al Mayadeen which aired on October 6, 2025 (Al Mayadeen)
Politics

Tehran never interferes in Hezbollah decisions: Representative in Iran

Smoke billows over the Gaza Strip following an Israeli bombardment, as seen from southern Palestine, Sunday, Oct. 5, 2025. (AP)
Politics

Indirect talks for a ceasefire in Gaza begin in Sharm El-Sheikh

Fighters from the Syrian Democratic Forces (SDF) prepare to attend a military parad in Qamishli, northeastern Syria, Tuesday, August 12, 2025 (AP)
Politics

Security forces seal Aleppo’s Sheikh Maqsoud, Ashrafieh districts

Amsterdam Captain Mohammed Ali Mohiuddin, who took part in the Global Sumud mission to Gaza, talks to Al Mayadeen on October 6, 2025 (Screengrab)
Politics

GSF captain says despite abuse, 'Israel weaker than spider's web'

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS